




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 9/04, A61K 31/70	A1	(11) International Publication Number: WO 00/42054 (43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: PCT/IB00/00022 (22) International Filing Date: 10 January 2000 (10.01.00) (30) Priority Data: 86/DEL/99 15 January 1999 (15.01.99) IN 09/276,368 25 March 1999 (25.03.99) US (71) Applicant (for all designated States except US): RANBAXY LABORATORIES LIMITED [IN/IN]; 19 Nehru Place, New Delhi 110 019 (IN). (72) Inventors; and (75) Inventors/Applicants (for US only): ARORA, Sudershan, K. [IN/IN]; B5/5 DLF Phase-I, Qutab Enclave, Gurgaon, Haryana 122 001 (IN). KISHORE, Nawal [IN/IN]; 15344, Sector 13, Kurukshetra, Haryana 136 118 (IN). GUPTA, Jang, Bahadur [IN/IN]; 349, Sector 14, Gurgaon, Haryana 122 001 (IN). JOSHI, Vishwas, D. [IN/IN]; Ranbaxy Research Labs, 220, A1, Phase I, Okhla Industrial Area, New Delhi 110 020 (IN).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 2,3-O-ISOPROPYLIDENE DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS  (57) Abstract This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O- isopropylidene-α -L-xylo-2-hexulofuranosonic acid, of formula (I) compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O- isopropylidene-α -L-xylo-2- hexulofuranosonic acid and the methods of treating such pathologies as listed above.		



G00001



162162